What It Is

Survodutide is a novel, long-acting dual agonist peptide targeting both Glucagon-Like Peptide-1 (GLP-1) and Glucagon (GCG) receptors. Synthesized as a glucagon derivative with fatty acid acylation for extended plasma clearance, it activates gut-brain satiety pathways while simultaneously stimulating hepatic energy expenditure.

What It Is Commonly Used For

• Hepatic Lipid & NASH/MASH Research: Studied extensively in metabolic liver disease models for its ability to reduce liver fat content, decrease inflammation, and prevent fibrotic progression via direct hepatic glucagon receptor activation.

• Dual-Mechanism Energy Expenditure: Evaluated for increasing basal metabolic rate and lipolysis through glucagon pathways while suppressing appetite and caloric intake through GLP-1 receptor activation.

• Profound Body Weight & Glycemic Control: Researched in advanced metabolic models for improving glucose tolerance, enhancing insulin sensitivity, and accelerating adipose tissue clearance.

General Purpose

To provide a dual GLP-1 and glucagon receptor agonist for investigating metabolic energy balance, hepatic fat reduction, non-alcoholic steatohepatitis (NASH/MASH) therapeutics, and weight management dynamics in laboratory research.

Specifications